Saez R A, Slease R B, Selby G B, Puckett C, Epstein R B, Mandanas R A, Confer D L
University of Oklahoma Health Sciences Center, Oklahoma City 73190.
J Okla State Med Assoc. 1994 Aug;87(8):358-63.
Non-Hodgkin lymphomas (NHLs) are a group of malignant disorders that can be cured with chemotherapy and/or radiotherapy in 30% to 50% of cases. For those who fail initial therapy, cure is rarely achieved with standard dose chemotherapy; therefore higher doses of chemotherapy have been used with autologous bone marrow support. This major medical center has performed 74 autologous bone marrow transplants (ABMT) for patients with non-Hodgkin lymphoma who had failed initial therapy between 1984 and 1993. Preparatory regimens included high doses of chemotherapy with or without radiotherapy. There were 14 patients with low grade, 41 with intermediate grade, and 18 with high grade histologies. Among patients with low grade histologies, 90% responded and 50% are relapse-free between 1 and 33 months post-ABMT. Among patients with intermediate and high grade histologies, 25% are relapse-free between 2 and 80 months post-ABMT.
Autologous bone marrow transplantation is effective in patients with relapsed non-Hodgkin lymphoma and should be considered an important therapeutic option.
非霍奇金淋巴瘤（NHLs）是一组恶性疾病，30%至50%的病例可通过化疗和/或放疗治愈。对于初始治疗失败的患者，标准剂量化疗很少能治愈；因此，已使用更高剂量的化疗并辅以自体骨髓支持。该大型医疗中心在1984年至1993年间为初始治疗失败的非霍奇金淋巴瘤患者进行了74例自体骨髓移植（ABMT）。预处理方案包括高剂量化疗，有或没有放疗。有14例低级别、41例中级别和18例高级别组织学类型的患者。在低级别组织学类型的患者中，90%有反应，50%在ABMT后1至33个月无复发。在中级别和高级别组织学类型的患者中，25%在ABMT后2至80个月无复发。
自体骨髓移植对复发的非霍奇金淋巴瘤患者有效，应被视为一种重要的治疗选择。
